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Abstract. Diffuse fluorescence tomography requires high contrast-to-background ratios to accurately reconstruct
inclusions of interest. This is a problem when imaging the uptake of fluorescently labeled molecularly targeted
tracers in tissue, which can result in high levels of heterogeneously distributed background uptake. We present
a dual-tracer background subtraction approach, wherein signal from the uptake of an untargeted tracer is subtracted
from targeted tracer signal prior to image reconstruction, resulting in maps of targeted tracer binding. The approach
is demonstrated in simulations, a phantom study, and in a mouse glioma imaging study, demonstrating substantial
improvement over conventional and homogenous background subtraction image reconstruction approaches. © The
Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part
requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.18.1.016003]
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1 Introduction
Fluorescence tomography (FT) is a promising molecular imag-
ing modality that is capable of mapping biomolecule distribu-
tions in tissue without requiring the use of ionizing radiation,
such as is required in competing nuclear medicine modalities.
However, while FT is very sensitive, the propagation of light
through tissue is hindered by a significantly greater amount of
scattering and absorption than ionizing radiation (e.g., x-rays),
limiting the depth of tissue that can be imaged through to several
centimeters.1 This depth limitation has restricted applications of
whole-body FT to small animal imaging to date, where it has
shown great promise as a preclinical tool for in vivo investiga-
tions of biomolecular pathways in disease states.2 This study
introduces an approach to doing diffuse FT that has some inher-
ent benefits in image reconstruction accuracy, as well as periph-
eral benefits by allowing imaging of molecular binding at very
short times after contrast injection in vivo.
Contrast in FT is typically based on the injection of a fluo-
rescently labeled molecular drug that will preferentially bind to
a specific biomolecule of interest (e.g., cellular receptors that are
over-expressed in pathological processes). Immediately after
injection, the tracer is dispersed throughout the body and over
time it is cleared from the plasma and tissues that are devoid of
the biomolecule of interest. It is retained in areas where it has
bound to the targeted biomolecule, thus providing fluorescent
contrast only in tissues where the receptor is ‘over-expressed.’
The strength of this approach is that the targeted molecule can be
synthesized to bind most biomolecules of interest, and as long as
the chosen biomolecule is in a region that can be accessed by the
tracer, the approach should be practicable. The problem with the
approach is that at early timepoints there can be significant
levels of background tracer uptake,3 and by waiting the hours
or even days necessary for the background to dissipate, it is
more likely for effects, such as cellular internalization or
metabolism of the tracer, to affect the relationship between fluo-
rescence and receptor density.4 Furthermore, at these extended
time points there may still be considerable nonspecific tracer
concentrations in organs of filtration like the liver, kidneys,
spleen, and bladder, confounding the ability to localize bound
fractions of the tracer, at least in the abdomen.5 This study devel-
ops one new approach toward advancing this area.
The nonlinearity of image reconstruction algorithms in FT
make background fluorescence severely detrimental to resolving
bound tracer populations of interest.6 In response, a number of
approaches have been designed to mitigate the effects of back-
ground: such as constraint-based reconstruction algorithms,7–11
spectral and lifetime removal of autofluorescence,12–14 preinjec-
tion image subtraction,15 and analytical modeling of background
fluorescence.6,16,17 However, while many of these approaches
work well for autofluorescence removal or removal of homo-
geneously distributed fluorescent backgrounds, they are not
ideal if the background is heterogeneous and predominantly
comprised of nonspecific fluorescent tracer uptake, which may
be expected in molecularly targeted FT studies at earlier time-
points after targeted tracer injection.18 In the present study, an
approach is proposed wherein the uptake of a second, untargeted
fluorescent tracer is used to subtract off the nonspecific uptake
of a simultaneously injected targeted fluorescent tracer. As long
as the two tracers have similar delivery characteristics (i.e., their
vascular permeability), nonspecific uptake, and pharmaco-
kinetics19—and the nonspecific fluorescence uptake is much
greater than the level of autofluorescence3—the untargeted
tracer fluorescence data can be used as a scaled surrogate of
the unbound component of the targeted tracer uptake, allowing
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a means of subtracting off the unbound (background) signal.
The strength of this is that the approach is feasible even if
the background is heterogeneous or is found in high concentra-
tions in organs of filtration.20 This development, originally pro-
posed in a previous study,21 is presented in detail in the current
study and explored through simulations, phantom experiments,
and in a pilot in vivo study.
2 Theory
2.1 Dual-Tracer Background Subtraction
When exciting fluorescent molecules within a biological tissue,
the measurement of reemitted fluorescent light at the surface can
be considered linear with respect to the fluorophore concentra-
tion in the limit that the absorption of the fluorophores is much
less than that of the main endogenous absorbers in tissue (in-
cluding hemoglobin, lipids and water).22 The dual-tracer back-
ground subtraction approach introduced in this study assumes
this linearity hypothesis holds at two wavelengths of interest,
namely the excitation wavelengths of a targeted and an un-
targeted fluorescent tracer. The general mathematical framework
for the single-wavelength linear FT inverse problem has been
presented elsewhere,23 and so here the methodology of a general
dual-wavelength FT problem is set up and solved. If m optical
measurements are made and the interrogated spatial domain is
discretized into n volume elements (e.g., finite elements or recti-
linear voxels), the linear problem can be expressed as a matrix
equation mapping the n-by-1 fluorescence yield vector, xi
(where i ¼ T represents the notation for data from a targeted
tracer and i ¼ U is notation for an untargeted tracer), to the
m-by-1 data vector, di, composed of fluorescence measured
at select source-detector pair positions on the surface of
the imaging domain at targeted and untargeted tracer wave-
lengths, λi:
Jixi ¼ di: (1)
The operator Ji is the m-by-n forward model or sensitivity
matrix defined at wavelengths λi. For a given imaging geometry
and spatial discretization, and in the diffusion limit,24 Ji is
strictly a function of the light absorption (μa) and reduced scat-
tering (μ 0s) properties of the imaging medium. These properties
vary amongst all n imaging domain elements and are included
in the vector μi: i.e.,
Ji ¼ JðμiÞ. (2)
To understand the utility of the untargeted tracer distribution as a
means of removing unwanted background signal from a targeted
tracer distribution (and potentially other factors unaccounted for
through modeling), the vectors xT and xU, representing the tar-
geted and untargeted tracer distributions, respectively, can be
expanded as follows:
xT ¼ xbound þ xbk þ xaf
xU ¼ xbk;u þ xaf;u; ; (3)
where the vector xbound represents the amount of targeted fluo-
rophore bound to its specific receptor at each element of the
domain, the vector xbk is the amount of unbound or ‘back-
ground’ targeted fluorescence at each element of the domain,
the vector xaf is the amount of autofluorescence (endogenous
fluorescence)25 at the wavelength used to detect the targeted
fluorescence, and the vectors xbk;u and xaf;u are the correspond-
ing background and autofluorescence distributions at the un-
targeted tracer wavelength. It should be noted that there is no
bound term in xU as a result of the untargeted tracer not being
able to bind to the specific receptors of the targeted tracer.
If the simultaneously injected untargeted tracer (fluorescing
at a different wavelength: typically >50 nm peak-to-peak sep-
aration) is assumed to have similar delivery characteristics to the
targeted tracer, the background distribution of the targeted tracer
can be approximated to be a linear function of the background
distribution of the untargeted tracer. For example, mathemati-
cally this would be, xbk ¼ c1xbk;u, where c1 is a constant that
accounts for effects such as differences in the system sensitiv-
ity at the targeted and untargeted tracer wavelengths and/or
differences in quantum efficiency or injected concentration be-
tween the two tracers. Similarly, a second hypothesis here is
that the autofluorescence at the targeted tracer wavelength
can be written as a linear function of the autofluorescence at
the untargeted tracer wavelength. This can be mathematically
expressed as, xaf ¼ c2xaf;u, where c2 is a constant that accounts
for differences in the magnitude of autofluorescence at the tar-
geted and untargeted tracer wavelengths. Therefore, Eq. (1) can
be re-written at the targeted and untargeted tracer wavelengths
as follows:








In order to accommodate the forward model matrix difference, a
third hypothesis is made that an ‘average’ sensitivity function,
J¯, can be defined as follows:
J¯ ≡ Jðμ¯Þ; (5)
where μ¯ is the mean of the optical properties in the vectors μT
and μU . This new sensitivity function is taken to have similar
mathematic properties to the matrices JT and JU and is used
henceforth. In addition, the fourth and last hypothesis is that
xaf ≪ xbk holds at both wavelengths, which is true for systemi-
cally injected near-infrared fluorescent tracers at least out to 24 h
after injection.3 If these four hypotheses are accurate, the differ-
ence of the two lines in Eq. (4) can be simplified to:
J¯xbound ¼ dT − c1dU: (6)
The scaling coefficient, c (redefined for brevity from c1), is dif-
ficult to calculate directly because the quantum efficiencies of
the two fluorophores are difficult to know exactly and the sen-
sitivity of the imaging system as a function of wavelength is
difficult to characterize. Instead, since most targeted FT appli-
cations assume binding will occur only within a set number of
inclusions within the imaging domain, it is assumed that for
some source-detector pair the relative contribution of bound tar-
geted signal to dT will be negligible.
6,17 Assuming this, c can be
estimated in the following way:
1. Find c0 such that maxðc0dUÞ ≤ 0.1 minðdTÞ.
2. Define dU;test ¼ 1.01pc0dU , where p is a positive
integer.
3. Find maximum p such that minðdT − dU;testÞ > 0.
4. Take c ¼ 1.01pc0.
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Thus a method is provided to build all parts of Eq. (6), save
the unknown bound distribution, which is the quantity of
interest.
2.2 Homogeneous Background Subtraction
If the background fluorescence is assumed to be relatively
homogeneous, then it may not be necessary to employ a second
untargeted tracer for the background subtraction.17 Rather,
homogeneous fluorescence background can potentially be
removed by substituting a simulated Born-normalized data
vector that assumes some level of homogenous fluorescence dis-
persed throughout the imaging domain in place of dU in Eq. (6).




To test the validity of the dual-tracer background subtraction
approach, two simulation studies were carried out. In the
first, the ability to locate a fluorescent inclusion in the presence
of increasing background (while not changing the contrast in
the inclusion) was investigated. Data were created from forward
model simulations on a 25-mm diameter two-dimensional (2-D)
circular mesh with 1521 nodes corresponding to 2496 triangular
elements, carried out using the open-source software, NIRFAST
(nirfast.org).26 Within the mesh, two 5-mm diameter inclusions
were simulated near half radii, separated by 90 deg [Fig. 1(a)].
Ten simulated datasets were created for fluorescent background
levels, μf, ranging from 0 to 10−6 mm−1, keeping a constant
contrast level of 10−6 mm−1 (i.e., the fluorescence in the inclu-
sions minus the fluorescence in the background was kept at a
steady 10−6 mm−1 level). This corresponded to a contrast-to-
background ratio (CBR) series ranging from infinite to unity.
To make the simulation as realistic as possible, the absorp-
tion and reduced scattering coefficients were set to μa ¼
0.0182 mm−1 and μ 0s ¼ 1.08 mm−1 at the excitation wave-
length, and μa ¼ 0.0164 mm−1 and μ 0s ¼ 1.01 mm−1 at the
emission wavelength of the simulated fluorophore. Fluores-
cence and transmittance data were simulated at 320 source-
detector pairs about the mesh based on the geometry of the
imaging system discussed in the following section. A 1%
level of Gaussian noise was added to both the fluorescence
and the transmittance datasets before ratioing the vectors to pro-
duce simulated Born-normalized datasets, the Born ratio being a
format routinely used in FT because of its mitigating effects on
model-data mismatch and a number of other approximations.23
This level of noise is commensurate with the typical level of
noise seen experimentally (results not shown).
Two approaches were employed to reconstruct fluorescence
distribution from the first set of simulated Born ratio data
using NIRFAST. Each employed an altered circular mesh with
1110 nodes and 2130 elements and a different set of assumed
optical properties, μa ¼ 0.0194 mm−1 and μ 0s ¼ 1.16 mm−1 at
the excitation wavelength, and μa ¼ 0.0152 mm−1 and μ 0s ¼
1.09 mm−1 at the emission wavelength, to avoid inverse crimes
and to account for the fact that experimentally, the optical prop-
erties cannot be known precisely. The first set of reconstructions
was carried out by reconstructing directly on the product of
the Born ratio data and a homogeneous forward model.13 The
second set of reconstructions was carried out using the
homogreneous background subtraction approach (see Sec. 2).
The same regularization parameter and stopping criterion were
used for both approaches.
In the second simulation study, two separate forward datasets
were produced to approximate the uptake distribution of both a
targeted and untargeted tracer. The targeted tracer forward data
were produced from the identical mesh as in the first simulation
(i.e., same mesh density, optical properties, and source-detector
locations), but were constructed with an inhomogeneous back-
ground. The absorption due to fluorescence inside the inclusions
was kept at 4 × 10−6 mm−1, while a spatially modulated level of
background fluorescence, ranging from 0 and 2 × 10−6 mm−1,
was created in a 2-D sinusoidal pattern with a periodicity of
10 mm [Fig. 2(a)], providing a mean tumor-to-background
ratio of 4∶1. The untargeted tracer forward data were produced
on the same mesh again, with the heterogeneous background
added, but with no inclusion [assuming no bound component,
see Fig. 2(b)], and using optical properties that were 10% greater
Fig. 1 Forward data were created based on a two-fluorescent inclusion
circular mesh, shown in (a). Reconstructed fluorescence distributions
resulting from increasing the level of background fluorescence while
keeping the contrast of the inclusion over the background the same
are presented in (b), (i)–(x). Each increment in Roman numeral corre-
sponds to an increase in the background of 10% of the contrast, provid-
ing a range of contrast-to-background ratios ranging from infinity to
unity. Reconstructions based on the data in (b) using the homogeneous
background subtraction approach are presented in (c) (i)–(x).
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than for the targeted tracer to approximate differences in absorp-
tion and scatter to be expected at the different wavelengths of the
tracers. Born ratio data was produced from these meshes in the
same manner as in the first set of simulations after 1% Gaussian
noise was added to the raw fluorescence and transmittance
datasets.
Three different reconstructions were carried out on these
heterogeneous background data, all using the same recon-
struction mesh with the same slightly erroneous optical proper-
ties described in the first simulation study. The first was a naïve
approach, reconstructing on the raw targeted tracer Born ratio
data alone. The second approach was the same homogeneous
background-subtract approach carried out on the first set of
simulated data. The final was the full dual-tracer approach char-
acterized by Eq. (6), where the simulated targeted tracer data
were substituted for dT and the simulated untargeted tracer data
were substituted for dU. The same regularization parameter and
stopping criterion were used in all cases and the reconstructions
were performed with NIRFAST.
3.2 Imaging System and Data Processing
To test out the dual-tracer background subtraction approach in
phantom and animal studies, fluorescence from targeted and
untargeted fluorescent tracers was imaged on a micro-computed
tomography-guided time-domain FT system. Much of the par-
ticulars of the system have been covered in depth previously,27,28
however, some significant changes were made to the system to
permit the simultaneous imaging of two fluorophores emitting at
two different wavelengths. A schematic of the dual-wavelength
version of the system is presented in Fig. 3(a). In brief, the FT
system is a noncontact fan-beam geometry system using two
pulsed-diode lasers (Picoquant, Berlin, Germany): one centered
at 635 nm and the other centered at 755 nm. For the experiments
carried out in this study, the lasers were pulsed at 40 MHz,
180 deg out of phase from each other. Each laser beam was
passed through a 10-nm band-pass filter (Chroma Technologies,
Bellows Falls, Vermont) centered at the respective wavelengths
of the lasers, before both beams were coupled into separate 50-
μm multimode optical fibers (Thorlabs, Newton, New Jersey).
Tests of the laser demonstrated that the 755 nm laser was more
powerful than the 635 nm laser, so as a means of having control
over the relative strengths of the two lasers, the output of the
755-nm laser fiber was passed through an in-line motorized var-
iable neutral density filter (OZ Optics, Ottawa, Ontario), before
the optical fibers from both lasers were coupled together into a
single 100-μm fiber using a custom-made fiber combiner (OZ
Optics, Ottawa, Ontario). The output of the fiber combiner was
then passed through a second variable neutral density filter to
control the overall excitation power of the system, and then
separated into two fibers using a 96∕4 in-line beamsplitter
(OZ Optics, Ottawa, Ontario). The 4% output was projected
onto a reference photomultiplier tube (PMT, Hamamatsu
Photonics, Japan) controlled by a time-correlated single photon
counting (TCSPC) card (Becker & Hickl GmbH, Berlin,
Germany) set to measure photon arrival times in a 25-ns window
at a resolution of approximately 24 ps. This allowed the tempo-
ral pulse spread functions (TPSFs) of both laser pulses to be
monitored during the experiment simultaneously [Fig. 3(b)].
The 96% output of the beamsplitter was coupled to the FT im-
aging gantry and focused onto the center of the gantry where the
imaging specimen was placed.
Opposite the excitation source on the gantry were five detec-
tion channels separated by 22.5 deg and focused to the center of
the gantry. The collected signal at each of these five positions was
separated into two channels, respectively, to monitor transmitted
excitation light and fluorescent light, simultaneously.27 The filters
employed in the fluorescence channels were custom-designed
multiple notch filters (Chroma Technologies, Bellows Falls,
Vermont) having high attenuation in 10-nm bandwidths centered
at the two laser wavelengths to effectively remove excitation light
from the path while allowing fluorescent light from both tracers to
pass through to the TCSPC-controlled PMT detectors. The
parameters of TCSPC detection of the fluorescence and transmit-
tance TPSFs were the same as those employed for the reference
PMT to allow the TPSFs from both lasers to be monitored. This
allowed the temporal position of the TPSFs to be used to separate
fluorescence from the different fluorophores in the imaging
medium, similar to ideas presented by others.29 The time-domain
dual-wavelength data was split into separate signals by wave-
length [e.g., Fig. 3(b)] and processed independently by taking
the area under the TPSF from the fluorescence channel and divid-
ing by the area under the TPSF from the transmittance channel to
produce ‘continuous-wave’-like Born ratio data at all source-
detector pairs and for each wavelength of laser. During data col-
lection, the laser intensity was automatically adjusted to ensure
the photon detection rate was no greater than 1% of the laser pulse
repetition rate (i.e., 40; 000 photons∕s) to avoid pulse-pile up
effects. The system and all data were calibrated and Born-ratioed
according to the procedures discussed in depth in another study,28
prior to applying the dual-tracer background subtraction ap-
proach, which was followed by image reconstruction.
3.3 Phantom Experiments
A 30-mm diameter cylindrical polymer phantom (INO, Quebec
City, Canada) was constructed with optical properties to mimic
tissue at near-infrared wavelengths. At an excitation wavelength
of 755 nm, the refractive index of the phantom was 1.4,
μa ¼ 0.018 mm−1, and μ 0s ¼ 1.07 mm−1. The phantom was
also constructed with three cylindrical inclusions running nearly
the length of the phantom: one inclusion was 8 mm in diameter
and the other two had a 4-mm diameter [Fig. 4(a)]. The 8-mm
diameter inclusion [left hole, Fig. 4(a)] was filled with a
combined 1∶1 nM solution of IRDye 800CW (LI-COR
Biosciences, Lincoln, Nebraska): Alexa Fluor 647 carboxylic
Fig. 2 Forward data were simulated on the fluorescence maps shown in
(a) and (b), representing the distribution of a targeted and untargeted
tracer, respectively. Reconstruction based only on data from (a) is
shown in (c), reconstruction on data from (a) using the homogenous
background subtraction is shown in (d), and reconstruction using the
dual-tracer background subtraction on data sets from (a) and (b) is
shown in (e).
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acid, succinimidyl ester (Life Technologies, Grand Island, New
York) in 1% intralipid in water to provide a background-type
inclusion characteristic of a nonspecific tracer accumulation
in an organ of filtration. The Alexa Fluor 647 was mixed in
water for at least 4 h prior to mixing to inactivate the ester bind-
ing site as per the manufacturer’s directions. The bottom and
right inclusions in Fig. 4(a) were filled with a 4∶4- and an
8∶4-nM ratio of the two tracers to represent an inclusion
with only nonspecific uptake (equivalent uptake of targeted
and untargeted tracers) and an inclusion with specific binding,
respectively. The two inclusions with equivalent concentrations
of targeted and untargeted tracer can also be thought of as
components of a heterogeneous background in reference to
the simulation studies. The phantom was then imaged on the
dual-wavelength fluorescent tomography system at 64 source
positions about its circumference (corresponding to 320
source-detector pairs). Data were averaged for 5 s at each source
position, yielding a total scan time of 12 min. NIRFAST recon-
structions were carried out on the raw Born-ratio data at the
IRDye 800CW wavelength, the raw Born-ratio data at the
Alexa Fluor 647 wavelength, and using the dual-tracer back-
ground subtraction approach governed by Eq. (6) where the
IRDye 800CW data was substituted for dT and the Alexa
Fluor 647 data was substituted for dU.
3.4 Animal Experiments
To test out the applicability of the dual-tracer background sub-
traction approach in an in vivo experiment, targeted and untar-
geted tracer concentrations were intravenously injected into
eight athymic mice, six with human glioma tumors implanted
in their left cerebral hemisphere, and two control mice. The pro-
cedure for growing the tumor is discussed in detail elsewhere.18
The tumor line used in this study was a U251 human neuronal
glioblastoma (provided by Dr. Mark Israel at Dartmouth
College, Hanover, New Hampshire), which is known to over-
express the cell surface molecule, epidermal growth factor re-
ceptor (EGFR).18 In response, an EGFR-targeted tracer, IRDye
Fig. 3 A schematic of the simultaneous dual-wavelength fluorescence tomography system is presented in (a). The system is shown here in a calibration
stage where the excitation light is diffused into all detection channels equally. The coupling of the lasers is depicted in the bottom portion of (a) where
black lines represent fiber optic cable connections from one component of the system to the next. The rotating, non-contact imaging gantry is depicted
in the middle of (a) and the detection setup is depicted above the gantry. ND represents a neutral density filter and PMT represents the photomultiplier
tube detectors. An example of the simultaneous collection of the pulsed light from the two laser sources is depicted in (b), the blue data corresponds to
the portion of the TPSF attributed to the 635 nm laser and the red data corresponds to that attributable to the 755-nm laser.
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800CW-EGF (LI-COR Biosciences, Lincoln, Nebraska) was
employed and Alexa Fluor 647 was employed as the untargeted
tracer. The Alexa Fluor 647 was mixed in water for at least 4 h at
room temperature prior to mixing with the targeted tracer before
injection to inactivate the ester binding site as per the manufac-
turer’s directions. This is done to minimize nonspecific binding
or binding to the targeted tracer. Two nmol of both tracers were
injected into a tail-vein of four mice (two controls and two tumor
mice). The imaging protocol and reconstructions were carried
out in the same manner as described in the Methods at 4 h
post tracer-injection in one tumor mouse and both controls, and
at 24 h postinjection in a second tumor mouse (the mouse
imaging required removal of data projections that intersected
with the mouse bed).28 The remaining four tumor mice were
imaged at 1 h after injection of 0.2 nmoles of IRDye 800CW
labeled anti-EGFR affibody (Affibody, Solna, Sweden) and
0.2 nmoles of Alexa Fluor 750 (Life Technologies, Grand
Island, New York) labeled negative control Affibody. The label-
ing was done using basic maleimide chemistry as per the
Affibody instruction manual. The uptake of both tracers was
imaged using an eight-channel magnetic-resonance imaging-
fluorescence spectroscopy system with excitation at 690 nm and
spectral fluorescence detection and fitting to resolve signal from
each tracer, simultaneously.13 Contrast-enhanced magnetic res-
onance imaging (MRI) was carried out on all mice 1 day prior
to fluorescent imaging on a Philips 3 T Achieva MRI scanner
(Philips Medical Systems, Andover, Massachusetts), 10 min
after injection of 100-mg∕kg gadopentetate dimeglumine
(Magnevist) to provide a secondary means of localizing the
tumor mass, details of which have been discussed previously.18
4 Results and Discussion
The results from the first simulation experiment wherein back-
ground fluorescence was incrementally increased in a circular
imaging domain with two circular inclusions, while keeping
contrast (inclusion fluorescence minus background fluores-
cence) the same are presented in Fig. 1. Figure 1(bi) to 1(x)
shows a reconstruction for each increase in background signal.
It is clear that the quality of the fluorescence reconstruction was
exceedingly sensitive to the level of background fluorescence,
with substantial artifacts appearing after the third image, corre-
sponding to a 4∶1 contrast-to-background ratio (CBR). The
same experiment was repeated for an order-of-magnitude higher
contrast (while keeping the CBRs the same) with no observed
change (results not shown). This apparent sensitivity of FT to
background signal, independent of contrast, has been described
previously,6,17 and is a significant limitation to fluorescence
tomography. As such, a number of efforts have been made to
mitigate background effects on FT by fitting autofluorescence
spectra, subtracting preinjection images from postinjection
images, removing background fluorescence through analy-
tical modeling, or constraining the reconstruction algo-
rithms.6,7,13,16,30,31 Figure 1(c) demonstrates the utility of a
simple background subtraction technique when using the homo-
geneous background subtraction approach (see Sec. 3) on the
data presented in Fig. 1(b). The result was that both inclusions
could be seen equally well for any level of background except
for in the zero-background image [(Fig. 1(ci)], where the result
was worse than the corresponding naïve reconstruction in
Fig. 1(bi). While the overall vast improvements in inclusion
localization were obvious from comparing the background sub-
tracted images in Fig. 1(c) with the raw-data-based images in
Fig. 1(b), further discussion is warranted to explore the utility
of the homogeneous background subtraction approach for
in vivo applications.
One component of the approach is that it requires optimiza-
tion of the scaling factor, c. As discussed in Sec. 2, c accounts
for any scaling differences between the targeted tracer dataset
and the background dataset (whether it is a forward model of
homogenous background, as in this case, or the distribution
of a second untargeted tracer, discussed below). This parameter
is attainable only if at least one source-data projection probes an
area of the imaging domain that is relatively void of bound tracer
(i.e., an area inhabited by only background fluorescence signal).
For most FT studies this assumption will likely hold, since in the
majority of cases, targeted fluorescence is used to highlight
localized pathologies in a larger field of view (such as a
small tumor). One potential problem with the methodology
of choosing c, however, is highlighted by the failure of the back-
ground subtraction approach when the original dataset is void of
background [Fig. 1(ci)]. This failure is owed to the inherent
assumption that there is at least some small level of background;
therefore, in the absence of background, a small amount of the
signal is still subtracted, causing fluorescence data arising from
the inclusion to be removed. Furthermore the determination of c
can be affected by noise in the data or spurious data collection
(e.g., animal motion) if the lowest signal data projections are
substantially affected. Figure 5 presents the results of an inves-
tigation into the sensitivity of the determination of c to noise in
the data [Fig. 5(a)], and the effect of errors in c on the accuracy
Fig. 4 Overlays of phantom optical reconstructions on x-ray CT images. Reconstruction based on only the targeted tracer excitation wavelength data is
shown in (a). Reconstruction based on only the untargeted tracer excitation wavelength data is shown in (b). The dual-tracer background subtraction
image based on both data sets is shown in (c).
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of dual-tracer image reconstruction [Fig. 5(b)]. Figure 5(a) dem-
onstrates that c will tend to be underestimated in the presence of
Gaussian noise up to 10% added to the simulated targeted and
untargeted data from the Fig. 1(bx) simulation, and Fig. 5(b)
suggests that an underestimation in c will cause less
reconstruction errors than an overestimation in c. This is likely
a result of problems associated with dealing with negative data
vectors in the image reconstruction.
Another important component of the homogeneous back-
ground subtraction approach is the assumption that the
background is homogeneous. If indeed the background fluores-
cence is homogenous, this approach is powerful since it
is not specific to any imaging geometry and does not require
a second tracer to be injected; however, the nature of in vivo
background fluorescence may be more complex. Background
fluorescence in the context of systemically injected targeted
fluorescent tracers is comprised of two constituents, nonspecific
fluorophore uptake (i.e., fluorescence arising from fluorescent
tracer concentrations that are not bound to the specific target
of interest), and autofluorescence (i.e., fluorescence arising
from endogenous fluorophores). While autofluorescence is a
major problem in the visible spectrum,32 it becomes much
less of an effect in the near-infrared wavelength range
(600 to 1000 nm), where many new tracers are being developed
to exploit this property, as well as relatively low absorption
properties. In fact, within the near-infrared spectrum, it is
much more likely that the background fluorescence signal is pre-
dominantly comprised of nonspecific tracer uptake.3 While this
fact means that the nonspecific tracer uptake autofluorescence
assumption made to derive Eq. (6) is adequate, heterogeneities
in biological tissue with respect to blood flow and vascular per-
meability mean that in vivo background fluorescence is likely
quite heterogeneous.
To test out the effect a heterogeneous background could have
on the homogeneous background subtraction approach used in
Fig. 1, another set of simulated data were created on the fluo-
rescent mesh depicted in Fig. 2(a). Figure 2(c) demonstrates that
the effect of the variable background renders it impossible for
raw fluorescent data to be used to reconstruct the location of the
inclusions of interest. This is not unexpected, as a more rigorous
examination of the effects of fluorescence heterogeneity on FT
demonstrated that reconstructions can be affected by hetero-
geneous background when the tumor-to-background contrast
is less than 100∶1.33 Likewise, even the homogeneous back-
ground subtraction method was not optimal in the face of the
heterogeneous background [Fig. 2(d)]. However, when a distri-
bution of a second, untargeted tracer was simulated [Fig. 2(b)],
matching the variable background of the simulated targeted
tracer distribution, the dual-tracer background subtraction
approach (see Sec. 2) was capable of effectively removing
the variable background, making the bound fluorescent tracer
inclusions visible [Fig. 2(e)]. It should be noted that in this sim-
ulation, 10% differences in optical properties were used to create
the targeted and untargeted tracer datasets, respectively, sug-
gesting that the proposed dual-tracer background subtraction
approach is insensitive to differences in optical properties at
the necessarily different wavelengths needed to resolve two trac-
ers, simultaneously. Furthermore, there will always be errors
associated with estimates of optical properties for any given
Fig. 5 The dual-tracer background subtraction approach requires a determination of the optimal scaling factor, “c”, to normalize the untargeted tracer
dataset to the targeted tracer dataset. The error in determining “c” based on the approach described in this paper as a function of Gaussian noise added
to the raw targeted and untargeted tracer data is depicted in (a). The dependence of image reconstruction accuracy on the error in “c” is depicted in (b)
where the accuracy of the reconstruction is represented by an area-under-the-curve (AUC) analysis of a receiver operating characteristic analysis for
determining the location of the simulated inclusions (an AUC ¼ 1 would be a perfect reconstruction).
Table 1 Tumor contrast achievable by reconstruction of the targeted-
tracer uptake, the untargeted-tracer uptake, and the dual-tracer
reconstruction for all mice expressed in terms of contrast-to-background
ratios (CBRs), which are (mean tumor signal-mean background signal)/
mean background signal. Each mouse is labeled by the time in hours
after tracer injection the imaging was carried out. The numbers in









1 h (1)a −0.57 −0.70 1.83
1 h (2) −0.33 −0.42 1.26
1 h (3) −0.59 −0.73 0.69
1 h (4) −0.36 −0.43 0.66
4 ha 0.01 −0.13 4.97
24 ha 4.36 2.75 7.21
1 h Control (1)a −0.53 −0.34 −0.02
1 h Control (2) −0.61 −0.44 −0.09
aImaging results are presented in Fig. 6
Journal of Biomedical Optics 016003-7 January 2013 • Vol. 18(1)
Tichauer et al.: Dual-tracer background subtraction approach for fluorescent molecular tomography
imaging domain; however, the results of this simulation take this
possible error into account as well, suggesting that the ‘best
guess’ forward model matrix introduced in Eq. (5) is likely
to be sufficient to reconstruct either tracer at its wavelength,
independently, given that a Born ratio formulation would be
used to suppress model error.
The results of the phantom study presented in Fig. 4 provide
experimental support for the utility of the dual-tracer back-
ground subtraction approach. The phantom consisted of three
inclusions with the largest used as an estimation of a background
level with low and equal concentration of targeted and untar-
geted tracer, a second inclusion was an estimation of an organ
of filtration with high, but also equal, concentrations of both
tracers, and the third inclusion was an estimation of a target
of interest, such as a tumor, with a very high concentration
of targeted tracer and a high concentration of untargeted tracer.
The high concentration of untargeted tracer would be expected
in tumors because of the enhanced permeability and retention
effect.34 The reconstructions of the targeted and untargeted
tracer datasets on their own are presented in Fig. 4(a) and
4(b), respectively. In both cases, all three inclusions were vis-
ible, which is not surprising since the background fluorescence
of the phantom is negligible and therefore approximates the
infinite contrast scenario in Fig. 1(ai). However, looking at
the targeted fluorescence distribution in Fig. 4(a), it is not
clear which of the inclusions is the ‘tumor’ inclusion. Only
by applying the dual-tracer background subtraction approach,
the reconstruction of which is shown in Fig. 4(c), could the
‘tumor’ inclusion clearly be realized. This demonstrates the abil-
ity of the approach to be used to remove heterogeneous back-
ground and large nonspecific uptake, such as might be expected
in organs of filtration (e.g., the liver or kidneys). A postrecon-
struction difference image of Fig. 4(a) and 4(b) was carried out
to compare to the result in Fig. 4(c), but no scaling value could
be found that did not result in significant edge artifacts (results
not shown). This highlights the importance of carrying out the
dual-tracer data differencing prior to reconstruction as opposed
to after reconstructing both tracer distributions, independently.
The results of the mouse imaging experiments are presented in
Table 1 and Fig. 6. Table 1 presents the results from image recon-
structions of targeted tracer uptake, untargeted tracer uptake,
and the dual-tracer approach for all mice in terms of ability to
localize the tumor (or in the case of the controls: an arbitrary
region of the brain) assessed by contrast-to-background ratio
Fig. 6 Overlays of in vivo optical reconstructions on x-ray CT images are shown in (a)–(c) for a control mouse at 1 h after dual-tracer injection, in (d)–(f)
for a tumor mouse at 1 h postinjection, in (h)–(j) for the tumor mouse at 4 h postinjection, and in (l-n) for the tumor mouse at 24 h postinjection.
Reconstruction based on only the targeted tracer excitation wavelength data is shown in (a), (d), (h), and (l), reconstruction based on only the untargeted
tracer excitation wavelength data is shown in (b), (e), (i), and (m), and the dual-tracer background subtraction image is shown in (c), (f), (j), and (n).
Contrast-enhanced MRI shows the location of the glioma in the corresponding tumor mice (g), (k), and (o).
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[CBR: (mean tumor signal—mean background signal)/back-
ground signal]. The table demonstrates that up to 4 h after the
injection the contrast in the tumor of either targeted or untargeted
tracer was negative (i.e., there was more nonspecific uptake of the
tracers in the tissue surrounding the tumor (brain and head) than
in the brain). However, the dual-tracer background subtraction
approach, which is sensitive to bound fractions of the targeted
tracer, demonstrated clear tumor contrast in all mice even at
the early 1 h postinjection time-points. The contrast-to-back-
ground ratio in the tumor tended to increase with time from
an average of 1.11 0.55 at 1 h to almost five at 4 h and upwards
of seven at 24 h postinjection, suggesting a greater abundance of
binding with increased time, which is expected for this U251
tumor line.20,35 Reconstructed images of the 24-h, 4-h, 1-h,
and one of the 1-h control mice are presented in Fig. 6. It warrants
noting that by the 24-h point it was possible to accurately resolve
the tumor using either the targeted tracer or the untargeted tracer
uptake image reconstructions, as well as the dual-tracer image, as
each demonstrated a high tumor CBR. The fact that the untar-
geted tracer also located to the tumor suggests a considerable
amount of nonspecific uptake in the tumor owing to enhanced
vascular permeability and retention effects.34 This further sug-
gests that a significant portion of the targeted tracer uptake in
the tumor may come from unbound signal, highlighting the
use of the secondary tracer to make more quantitative assessments
of tracer-binding and receptor abundance, even at late time-points
after injection. Results from the two control mice imaged at 1 h
after injection demonstrated some accumulation of targeted and
untargeted tracer concentration in the tissue below the skull,
which is where the carotid arteries and other large blood vessels
can be found, while the dual-tracer reconstructions demonstrated
relatively homogenous distributions.
It should be noted that the success of the dual-tracer back-
ground subtraction methodology presented in this study is
Fig. 7 Born ratio data (fluorescence/transmittance) for the heterogeneous background simulated dataset, the phantom dataset, and a 1 h postinjection
mouse dataset are presented in (a)–(c), respectively. The red data represents the Born ratio as a function of source-detector pair number for the targeted
tracer data, the blue data represents the same thing for the corrected untargeted tracer data (i.e., cdU), and the green data represents the subtraction of
the untargeted dataset from the targeted dataset (i.e., red minus blue). The data are arranged that all projections from a single detector are combined in
columns separated by the vertical black lines. The number of detectors is higher in (c) than in (a) and (b) because this data set was collected with a
different fluorescence tomography system (see Sec. 3).
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highly dependent on the selection of a suitable targeted/untar-
geted tracer pair. Both tracers must have similar transport
kinetics (i.e., vascular permeability), similar plasma pharmaco-
kinetics (i.e., be metabolized similarly), and similar levels of
nonspecific uptake and binding. While the IRDye 800CW-
EGF is significantly larger than Alexa Fluor (∼7 versus.
1.3 kDa), all of these listed factors have been demonstrated
to be approximately equivalent for another similar tracer pairing:
IRDye 800CW-EGF and untargeted IRDye 700DX.20,35–38
The choice of Alexa Fluor 647 as an untargeted tracer in the
current study to replace IRDye 700DX was based on the wave-
length requirements of the FT system employed and the fact that
the tracer has a similar size to IRDye 700DX (1.3 versus
1.9 kDa), both being known for having low nonspecific binding.
While a more rigorous study is needed to determine the extent of
suitability of Alexa Fluor 647 to be used as an untargeted tracer
for IRDye 800CW-EGF, the simulation and phantom results pre-
sented in this study do not rely on this suitability and the in vivo
results of the present study suggest that its employment can
help improve tumor contrast in FT at early time-points after
tracer injection. Despite this, before employing a dual-tracer
background subtraction, the suitability of the targeted/
untargeted tracer should be evaluated on a case-by-case basis.
Furthermore, future studies using this dual-tracer background
subtraction algorithm could investigate the use of more sophis-
ticated single-targeted molecules with two fluorescent mole-
cules, one that would activate upon binding and one always
active as presented by Chen et al.,39 as a means of avoiding
the need to choose a suitable tracer pairing, thus avoiding
problems of differential uptake between the tracers.
5 Conclusions
A potential procedure for accurate background subtraction was
presented to improve targeted-tracer fluorescence molecular
tomography. Essentially, tomographic signal from the uptake
of a second untargeted tracer is used to subtract off the compo-
nent of the targeted tracer signal that arose from nonspecific
uptake [see example of raw data subtractions in Fig. 7 for sim-
ulation (a), a phantom study (b), and a mouse experiment (c)].
Support has been shown in multiple simulations, a phantom
study, and in a orthotopic glioma mouse model. These tests
demonstrate the ability of this methodology to allow recovery
of contrast that would be unrecoverable with conventional
FT. The peripheral benefit of this approach is that there are few
time constraints on when this type of imaging can be done
in vivo, opening up a range of applications in molecular imaging
that would be otherwise unattainable.
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